Pure Global AI
NCT06416475Recruitment Completed

The Effect of Mankai on Glycemic Control Among Patients With T2D

The Effect of Wolffia Globosa (Mankai) on Glycemic Control Among Patients With Type 2 Diabetes; A 3-month Randomized Controlled Pilot Trial
Ben-Gurion University of the NegevPhase 2ClinicalTrials.govdietary supplement
Verified
Study focus
Disease/Condition
Diabetes Mellitus, Type 2
Drug/Device/Intervention
Mankai supplementation
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
Ben-Gurion University of the Negev
Location
Be'er Sheva, Israel
Timeline & enrollment
Phase
Phase 2
Start date
Apr 30, 2024
End date
Aug 15, 2024
Enrollment
104 participants
Primary outcome

HbA1c,Fasting glycemic and insulin resistance profiling

Summary

The investigators aim to explore the effect of daily supplementation of Wolfia globosa Mankai
 on HbA1c and insulin resistance response among participants with type 2 diabetes (T2D). The
 investigators hypothesize that adding daily Mankai to T2D's healthy nutrition might lower
 HbA1c and promote glycemic control.
 
 Methods: A 3-month pilot RCT among 104 patients with T2D, with two intervention arms
 consuming comparable bottle volumes of either crude plant Mankai beverage (60ml Mankai) or
 water (60ml) 3 times/day postprandially over 3 months. Blood, urine, fecal, and clinical
 measures will be taken at 0 and 3 months. Overall appetite, food intake, symptoms, and
 medical treatment will be monitored.
 
 Importance: This study's results will shed light on the effects of regular Mankai consumption
 on HbA1c among patients with T2D, which may reveal a new nutritional source to improve
 glycemic control in T2D.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06416475
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06416475 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ben-Gurion University of the Negev and is currently Recruitment Completed. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 104 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.